1 hour ago
4
Keith Noonan, The Motley Fool
Sun, August 9, 2026 astatine 12:13 PM CDT 3 min read
AdaptHealth (NASDAQ: AHCO) banal got crushed this week aft the institution reported disappointing quarterly results. The company's stock terms ended the week's trading down 47% from wherever it stood astatine the extremity of the erstwhile week's marketplace close.
AdaptHealth reported its second-quarter results earlier the marketplace opened connected Aug. 4, with some income and net for the play coming successful beneath the market's expectations. With the large pullback this week, AdaptHealth banal is present down 38% implicit the past year.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
AdaptHealth's Q2 results were a large disappointment
AdaptHealth's Q2 results came successful acold beneath Wall Street's targets. While the mean expert estimation had targeted a per-share nett of $0.15 successful the quarter, the concern really coiled up posting a nonaccomplishment of $1.07 per stock successful the period.
Sales accrued astir 12.7% twelvemonth implicit twelvemonth to scope $740.3 million, but the show came successful astir $106.5 cardinal little than the mean expert forecast. Registered users connected the company's myApp level accrued astir 56% twelvemonth implicit twelvemonth to scope 512,000 but idiosyncratic maturation for the work hardly excited investors successful airy of anemic second-quarter numbers and downward guidance revisions.
AdaptHealth besides issued disappointing guidance
With its Q2 report, AdaptHealth issued caller guardant guidance that disappointed investors. The institution present expects income to travel successful betwixt $2.85 cardinal and $2.89 billion. The institution had antecedently guided for income to beryllium betwixt $3.45 cardinal and $3.52 cardinal for the year. Meanwhile, the mean expert estimation had called for income of astir $3.49 billion. The large downward revision was mostly owed to the discontinuation of its Diabetes Health concern and shifting its guidance to lone see continuing operations, but the forecast was disappointing nonetheless.
Non-GAAP (adjusted) net earlier interest, taxes, depreciation, and amortization (EBITDA) is present expected to travel successful betwixt $490 cardinal and $520 cardinal -- down from its erstwhile guidance scope betwixt $680 cardinal and $730 million. Including contributions from discontinued units, the institution is present targeting escaped currency travel (FCF) betwixt $80 cardinal and $120 cardinal -- down from its erstwhile guidance for FCF to beryllium betwixt $175 cardinal and $225 million. AdaptHealth's Q2 show and caller guidance person raised immoderate large questions, and there's unit connected the institution to amusement that it tin close the ship.
English (CA) · 
English (US) · 
Spanish (MX) ·